Cargando…

Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study

Background: Epithelioid mesothelioma (EM) is the commonest subtype of malignant pleural mesothelioma. Its histopathological discrimination from reactive mesothelial hyperplasia (RMH) could be challenging. Thus, an immunohistochemical panel is mandatory for better discrimination. BAP1 is a newly iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hakim, Sarah Adel, Abou Gabal, Hoda Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Society Journal Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262140/ https://www.ncbi.nlm.nih.gov/pubmed/34257556 http://dx.doi.org/10.3389/pore.2021.600073

Ejemplares similares

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
por: Bruno, Rossella, et al.
Publicado: (2016)

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Puskas, Rita, et al.
Publicado: (2021)

BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma
por: Murrone, Albero, et al.
Publicado: (2021)

FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience
por: Hrudka, Jan, et al.
Publicado: (2021)

Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
por: Mokánszki, Attila, et al.
Publicado: (2021)

Reactive mesothelial hyperplasia mimicking mesothelioma in an African green monkey (Chlorocebus aethiops)
por: Plesker, Roland, et al.
Publicado: (2020)

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
por: Barnett, Sarah E., et al.
Publicado: (2023)

Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
por: Ollila, Hely, et al.
Publicado: (2022)

Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma
por: Saddozai, Umair Ali Khan, et al.
Publicado: (2022)

Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 “SLC34A2” in Papillary Thyroid Carcinoma: An Immunohistochemical Study
por: Hakim, Sarah Adel, et al.
Publicado: (2021)

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping
por: Di Stefano, Iosè, et al.
Publicado: (2023)

HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line
por: Stockhammer, Paul, et al.
Publicado: (2021)

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study
por: Ghanim, B, et al.
Publicado: (2015)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
por: Hiratsuka, Takuya, et al.
Publicado: (2022)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells
por: Takehara, Yusuke, et al.
Publicado: (2018)

Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells
por: Takehara, Yusuke, et al.
Publicado: (2018)

Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?
por: Ozdemir, Hanife Gulnihal, et al.
Publicado: (2020)

KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma
por: Vannucchi, Margherita, et al.
Publicado: (2023)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma
por: Nada, Ola H, et al.
Publicado: (2014)

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
por: Cornelissen, Robin, et al.
Publicado: (2014)

Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy
por: Fortarezza, Francesco, et al.
Publicado: (2021)

Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
por: Klotz, Laura V., et al.
Publicado: (2022)

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
por: Osmanbeyoglu, Hatice Ulku, et al.
Publicado: (2022)

Cytomorphology of nodular histiocytic/mesothelial hyperplasia
por: Jin, Xiaobing, et al.
Publicado: (2022)

A Biphasic Pleural Tumor with Features of an Epithelioid and Small Cell Mesothelioma: Morphologic and Molecular Findings
por: Hackman, Sarah, et al.
Publicado: (2016)

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
por: Nelhűbel, Györgyi A., et al.
Publicado: (2021)

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13
por: Martínez-Fernández, Carmen, et al.
Publicado: (2023)

Pleural Epithelioid Hemangioendothelioma
por: Lee, Young Joo, et al.
Publicado: (2008)

Large‐scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma
por: De Rienzo, Assunta, et al.
Publicado: (2020)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively
por: Sato, Tatsuhiro, et al.
Publicado: (2021)

A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
por: Pina, Marta, et al.
Publicado: (2022)

Loss of BAP1 function leads to EZH2-dependent transformation
por: LaFave, Lindsay M., et al.
Publicado: (2015)

Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study
por: Mannarino, Laura, et al.
Publicado: (2022)

Primary intrahepatic malignant epithelioid mesothelioma
por: Perysinakis, Iraklis, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vq5m9nvk5a3ish1l7cr7p75sd7